CJ and Pfizer Korea jointly to promote Campto.

Published: 2005-06-07 06:56:00

Updated: 2005-06-07 06:56:00

CJ pharmaceutical division and Pfizer Korea have made a joint marketing promotion agreement for Campto (Irinotecan Hcl), a anti-cancer drug for the metastasis colon cancer starting from June 1, which may provide a chance for the both parties to create a synergic effects in the marketing and selli...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK